Alnylam Pharmaceuticals, Inc Forecast, price target & analysts
Alnylam Pharmaceuticals, Inc Target price 2026 - Analyst rating & recommendation
Alnylam Pharmaceuticals, Inc Classifications & Recommendation
Alnylam Pharmaceuticals, Inc Price Target
| Target Price | $357.00 |
| Price | $165.00 |
| Potential | 116.36% |
| Number of Estimates | 31 |
| 31 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2027 . The average Alnylam Pharmaceuticals, Inc target price is $357.00. This is 116.36% higher than the current stock price. The highest price target is $594.30 260.18% , the lowest is $238.36 44.46% . | |
| A rating was issued by 38 analysts: 29 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2027 of 116.36% . Most analysts recommend the Alnylam Pharmaceuticals, Inc stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
34 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2026 . The average Alnylam Pharmaceuticals, Inc sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
12 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2026. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
34 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2026. The average Alnylam Pharmaceuticals, Inc net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
34 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
Alnylam Pharmaceuticals, Inc...
Current Alnylam Pharmaceuticals, Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Raymond James |
Strong Buy
➜
Outperform
|
Downgrade | Oct 30 2026 |
| Bernstein |
Outperform
➜
Market Perform
|
Downgrade | Oct 30 2026 |
| Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 30 2026 |
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Oct 30 2026 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 30 2026 |
| Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Oct 30 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Downgrade
Raymond James:
Strong Buy
➜
Outperform
|
Oct 30 2026 |
|
Downgrade
Bernstein:
Outperform
➜
Market Perform
|
Oct 30 2026 |
|
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Oct 30 2026 |
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Oct 30 2026 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 30 2026 |
|
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Oct 30 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 30 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
